Mirum Pharmaceuticals, Inc. - common stock — Filings & Documents (NASDAQ:MIRM) — Page 12 | MetaTrader

展开完整图表

Financials

概览声明统计 Documents

2019

Current report, Q3 FY2019

Mirum Pharmaceuticals, Inc. current report, Q3 FY2019

Quarterly report, Q2 FY2019

Mirum Pharmaceuticals, Inc. quarterly report, Q2 FY2019

1
...
5
6
7
8
9
10
11
12

新闻

RBC资本维持对Mirum Pharmaceuticals的“跑赢大盘”评级，将目标价上调至155美元

Baird维持对Mirum Pharmaceuticals的“跑赢大盘”评级，将目标价上调至130美元

Mirum Pharmaceuticals和Incyte与Regeneron竞争治疗异常骨骼形成

Citizens重申Mirum Pharmaceuticals评级,看好试验进展

Mirum完成胆汁淤积性瘙痒症试验患者招募

Mirum Pharmaceuticals在Leerink会议上公布战略增长计划

Mirum Pharmaceuticals在Citizens生命科学大会:战略管线推进

摩根士丹利重申Mirum Pharmaceuticals股票增持评级

Evercore ISI上调Mirum Pharmaceuticals目标价,看好管线进展

Mirum Pharmaceuticals在TD Cowen会议上的表现:聚焦罕见病战略

Leerink将Mirum Pharmaceuticals目标价下调至118美元

Evercore ISI重申Mirum Pharmaceuticals股票评级为跑赢大盘